Short-term Changes in Thyroid-Stimulating Hormone Level after Body Fat Reduction via Partial Meal Replacement

Article information

Korean J Fam Med. 2023;44(1):58-63
Publication date (electronic) : 2023 January 19
doi :
Department of Family Practice and Community Health, Ajou University School of Medicine, Suwon, Korea
Corresponding Author: Nam-Seok Joo Tel: +82-31-219-5324, Fax: +82-31-219-5218, E-mail:
Received 2022 July 8; Revised 2022 October 21; Accepted 2022 October 25.



Serum thyroid-stimulating hormone (TSH) levels change during body weight reduction. However, the changes that occur during short-term body weight control interventions remain controversial. Thus, this study aimed to evaluate the changes in TSH levels according to body fat reduction.


We performed a 3-month intervention study involving partial meal replacement. Forty-nine participants completed the study. Correlations between changes in TSH levels and other body composition parameters were determined. The subjects were divided into two groups according to their body fat reduction (>1 kg, n=20; <1 kg, n=29). The changes in metabolic parameters, including TSH levels, were compared. For significant values, a multivariate analysis was performed after adjustment to evaluate the relationship between TSH changes and body fat reduction.


The 3-month intervention caused favorable changes in body proportions and metabolic parameters. TSH levels changed significantly only after changes in total body fat, showing a partial correlation. Changes in TSH levels were significantly different between groups (P=0.014). Moreover, the change in TSH levels was significantly different after adjustment (P=0.012).


A body fat reduction, especially >1 kg, can reduce serum TSH concentrations in subjects with metabolic syndrome after short-term body weight intervention.


Metabolic syndrome is a well-known cardiovascular disease. Central obesity, one major factor of metabolic syndrome, is reportedly closely associated with cardiovascular morbidity and mortality [1]. Therefore, a reduction in body weight via exercise and diet control is the main strategy to prevent cardiovascular diseases in patients with metabolic syndrome. A previous study showed that meal replacement with mixed rice controls weight and improves the antioxidant enzyme activities of obese women [2]. We also reported that black rice with giant embryos can improve metabolic derangement through weight control and reducing vascular inflammation [3]. Therefore, the long-term use of partial meal replacement with rice powder may effectively reduce fat mass and improve various metabolic parameters.

Levels of thyroid hormones can change during the weight control period. Thyroid hormones play important roles in the regulation of lipid metabolism. Only a slight change in serum thyroid hormone concentration can cause local fat accumulation and increase body mass [4,5]. Recent studies reported that thyroid-stimulating hormone (TSH) can be directly blinded to the TSH receptor in tissues outside the thyroid (such as the adipose tissue), thereby having external effects [6]. However, most studies of the relationship between thyroid hormone parameters are derived from drastic interventions, such as bariatric surgery or the manipulation of macronutrient composition [7-9], while limited information is available about thyroid hormone metabolism during weight loss achieved by partial meal replacement. Moreover, changes in TSH levels can be interpreted as an adaptation to a reduced fat content. After adaptation, the total body energy expenditure is reduced to some extent. This might be a cause of difficulty maintaining a reduced body weight. Therefore, this study aimed to explore the changes in TSH levels in body weight reduction subjects with metabolic syndrome, especially in the fat reduction group, during a 3-month weight control program consisting of partial meal replacement.


1. Study Design and Subjects

These methods were described in our previous study in which we evaluated changes in metabolic biomarkers after partial meal replacement (black rice or white rice) for 3 months [3]. Subjects aged 20–59 years with a body mass index of 25–30 kg/m2 were included. Subjects received 1 month of meal supplements consisting of black rice with a giant embryo or white rice instead of breakfast at every monthly visit. The meal replacement was provided in the same colored disposable small plastic bag containing black rice with giant embryos or white rice. The participants were asked to maintain their usual exercise and food intake.

Subjects who had a black rice allergy, type 2 diabetes, knee osteoarthritis, chronic obstructive lung disease, tuberculosis, hypothyroidism, or recent cardiovascular diseases (myocardial infarction and variant angina); who were currently pregnant or breastfeeding; or had psychological problems or cancers were excluded. Patients taking various steroids were also excluded from the study.

Fifty-one participants with metabolic syndrome were recruited for this study. Two dropped out due to moving to other cities. Finally, 49 subjects finished the study. Subjects who had metabolic syndrome and were >20 years of age participated in this study after providing voluntary consent. In the present study, we did not divide the subjects into black and white rice groups. Instead, we divided the subjects into two groups according to the amount of body fat loss (fat reduction >1 kg, n=20; fat reduction <1 kg, n=29) to compare TSH levels between them. The Institutional Review Board of Ajou University Hospital approved this study (approval no., AJIRB-MED-CT3-15-248) after obtaining proper informed consent.

2. Measurements

Metabolic parameters such as fasting glucose, insulin, lipid (Toshiba 200FR automatic analyzer; Toshiba Medical Systems, Tokyo, Japan), cortisol, high-sensitivity C-reactive protein (hs-CRP; Dade Behring Marburg GMBH, Marburg, Germany), and thyroid hormone (TSH and free T4) levels were assessed, while body proportions were measured by dual-energy X-ray absorptiometry (DISCOVERY-W fan-beam densitometry; Hologic Inc., Marlborough, MA, USA) before and after the intervention (at baseline and 3 months). Body weight, waist circumference, blood pressure (standard mercury manometer with the participant in a sitting position for 5 minutes prior to measurement), and adverse effects were also evaluated by a registered research nurse at every visit. Total calorie intake was assessed using a self-administered 24-hour food diary by a trained dietitian monthly. Metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel III) was defined as the presence of three or more of the following risk determinants: (1) central obesity (waist circumference: ≥90 cm in men, ≥85 cm in women); (2) high fasting glucose level (≥126 mg/dL); (3) high blood pressure (≥130/85 mm Hg) at rest; (4) high triglyceride level (≥150 mg/dL); and (5) low high-density lipoprotein cholesterol (≤40 mg/dL in men, ≤50 mg/dL in women). Blood tests were performed after overnight 8-hour fast.

3. Statistics

All values are presented as mean±standard deviation. Data from all study subjects before and after the intervention were compared using a paired t-test. Correlations between changes in body composition and TSH levels were also evaluated by partial correlation after the adjustment for age, sex, smoking, alcohol intake, and moderate-intensity exercise. Subjects were divided into a >1 kg body fat reduction group and a <1 kg body fat reduction group. In this study, the number of participants was not large enough to be categorized. Therefore, the cutoff value for body fat reduction was determined as 1 kg. The mean changes in metabolic parameters were compared between groups. We also compared significant values after adjusting for age, sex, smoking, alcohol intake, and moderate-intensity exercise using a general linear model. Statistical significance was set at P<0.05. The data were analyzed using IBM SPSS ver. 19.0 (IBM Corp., Armonk, NY, USA).


The anthropometric and metabolic parameters of the study subjects at baseline and 3 months after the intervention are summarized in Table 1. As predicted, the subjects had elevated triglyceride levels and waist circumferences at baseline. After the 3-month intervention, body weight, waist circumference, total fat mass, diastolic pressure, and hs-CRP levels were significantly reduced. However, TSH and free T4 concentrations showed no significant changes.

Anthropometric and metabolic parameters of study subjects (n=49) at baseline versus 3 months after intervention

Changes in TSH levels showed a positive correlation with total fat changes after adjustment (P=0.009) (Figure 1). The partial correlations of TSH changes with body composition are shown in Table 2. TSH was significantly correlated with changes in total fat mass (P=0.009) after the adjustment for age, sex, smoking, alcohol consumption, exercise, and hypertension.

Figure. 1.

Correlations between total body fat changes and thyroid-stimulating hormone (TSH) changes after adjustment.

Partial correlations of thyroid-stimulating hormone changes with other body composition changes

We divided the subjects into two groups according to the amount of fat reduction and investigated the changes in metabolic parameters (Table 3). Changes in serum TSH concentrations in the group with a fat reduction of >1 kg showed a significant decrease (P=0.014). After the adjustment for age, sex, smoking, alcohol consumption, and moderate-intensity exercise, TSH still showed a significant decrease in the group with a fat reduction of >1 kg (P=0.012) (Table 4).

Metabolic parameters by body fat reduction group

Changes in TSH according to body fat reduction


The present study showed a significant decrease in serum TSH concentration among subjects with metabolic syndrome who experienced a body fat reduction of >1 kg after a 3-month intervention of partial meal replacement with rice powder. The relationship between thyroid hormone levels and body fat mass remains unclear. In an interventional trial of 47 overweight subjects, TSH and triiodothyronine levels were significantly associated with fat mass at baseline [10]. In a crosssectional study of euthyroid adults with known vascular disease, higher serum TSH levels were associated with increased visceral fat thickness among individuals aged 67–80 years [11]. A previous study of 303 healthy volunteers demonstrated that the amount of subcutaneous fat was positively correlated with TSH level [12]. However, conflicting results have also been reported. A prospective study using meal supplements showed no significant difference in TSH levels between the body fat reduction group and other groups [13]. A controlled follow-up study reported that thyroxine treatment in patients with hypothyroidism increased the resting energy expenditure and decreased body weight, whereas fat mass was unchanged with weight loss, primarily due to the excretion of excess body water [14].

It is well established that thyroid hormone status is correlated with energy expenditure [15]. Thyroid hormones can stimulate both lipogenesis and lipolysis, although the net effect is fat loss when thyroid hormone levels are elevated [16]. Fatty acids produced from thyroid hormone– induced lipolysis are substrates for increased thermogenesis [17]. Bile acid–stimulating pathways include direct actions on cholesterol metabolism. They can also stimulate 5-deiodinase type 2 activity and thyroid hormone–mediated increases in energy expenditure. Although the reason for the decrease in TSH levels among those with decreased body fat is not entirely clear, we assume that it is an adaptive process that decreases energy expenditure and encourages fat accumulation [18]. Leptin may also play a role in regulating TSH and fat mass. Leptin is known to regulate the production of thyrotropin-releasing hormone in neurons within the periventricular nucleus [19,20]. Moreover, leptin can activate thyrotropin-releasing hormone neurons via Janus kinase/signal transducers and transcription pathway activators [20,21]. An increase in thyrotropin-releasing hormone levels can lead to a higher pituitary secretion of TSH [21-23].

The effects of body weight reductions on thyroid status were recently investigated. Among 783 obese patients who underwent a bariatric surgery evaluation, 18.1% had elevated serum TSH levels [24]. In a crosssectional analysis of data from the National Health and Nutrition Examination Survey, among 3,114 euthyroid adults without a history of thyroid disease, body mass index and waist circumference were positively associated with serum TSH levels [25]. Some studies have reported that weight loss can lead to normalized serum TSH levels [24]. However, serum TSH concentration made no difference between before and after meal replacement in our study. This may be related to the concept of the lipostatic setpoint as a time interval for weight regulation. We found that TSH levels could change within normal ranges with reductions in body fat. Although long-term intervention trials are needed, short-term reductions in body fat are associated with TSH changes, which can be related to total body fat or body weight reductions. Therefore, clinicians should recognize TSH changes according to changes in body fat as well as metabolic parameters.

This study had some limitations. First, it evaluated only short-term changes. Second, our data analysis involved a small number of subjects other than those in the conventional diet program. Thus, the results of our study should be confirmed in larger trials.

In conclusion, body fat reductions, especially those >1 kg, can change the serum TSH concentrations of subjects with metabolic syndrome. Long-term intervention studies are warranted to validate these findings.



No potential conflict of interest relevant to this article was reported.


This study was funded by the National Institute of Crop Science, Rural Development Administration of the Republic of Korea.


1. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007;17:319–26.
2. Kim JY, Kim JH, Lee DH, Kim SH, Lee SS. Meal replacement with mixed rice is more effective than white rice in weight control, while improving antioxidant enzyme activity in obese women. Nutr Res 2008;28:66–71.
3. Joo NS, Han SI, Kim KN, Kim KM, Kim BT, Park SB, et al. Black rice with giant embryo ameliorates serum C-reactive protein in adults with metabolic syndrome. J Clin Biochem Nutr 2020;67:344–8.
4. Iwen KA, Schroder E, Brabant G. Thyroid hormones and the metabolic syndrome. Eur Thyroid J 2013;2:83–92.
5. Javed A, Balagopal PB, Vella A, Fischer PR, Piccinini F, Dalla Man C, et al. Association between thyrotropin levels and insulin sensitivity in euthyroid obese adolescents. Thyroid 2015;25:478–84.
6. Williams GR. Extrathyroidal expression of TSH receptor. Ann Endocrinol (Paris) 2011;72:68–73.
7. Nannipieri M, Cecchetti F, Anselmino M, Camastra S, Niccolini P, Lamacchia M, et al. Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes: effects of weight loss. Int J Obes (Lond) 2009;33:1001–6.
8. Danforth E Jr, Horton ES, O’Connell M, Sims EA, Burger AG, Ingbar SH, et al. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest 1979;64:1336–47.
9. Kaptein EM, Beale E, Chan LS. Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. J Clin Endocrinol Metab 2009;94:3663–75.
10. Agnihothri RV, Courville AB, Linderman JD, Smith S, Brychta R, Remaley A, et al. Moderate weight loss is sufficient to affect thyroid hormone homeostasis and inhibit its peripheral conversion. Thyroid 2014;24:19–26.
11. Prats-Puig A, Sitjar C, Ribot R, Calvo M, Clausell-Pomes N, Soler-Roca M, et al. Relative hypoadiponectinemia, insulin resistance, and increased visceral fat in euthyroid prepubertal girls with low-normal serum free thyroxine. Obesity (Silver Spring) 2012;20:1455–61.
12. Alevizaki M, Saltiki K, Voidonikola P, Mantzou E, Papamichael C, Stamatelopoulos K. Free thyroxine is an independent predictor of subcutaneous fat in euthyroid individuals. Eur J Endocrinol 2009;161:459–65.
13. Aoe S, Yamanaka C, Ohtoshi H, Nakamura F, Fujiwara S. Effects of daily kelp (Laminaria japonica) intake on body composition, serum lipid levels, and thyroid hormone levels in healthy Japanese adults: a randomized, double-blind study. Mar Drugs 2021;19:352.
14. Karmisholt J, Andersen S, Laurberg P. Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. J Clin Endocrinol Metab 2011;96:E99–103.
15. Hones GS, Rakov H, Logan J, Liao XH, Werbenko E, Pollard AS, et al. Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo. Proc Natl Acad Sci U S A 2017;114:E11323–32.
16. Oppenheimer JH, Schwartz HL, Lane JT, Thompson MP. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 1991;87:125–32.
17. Trivieri MG, Oudit GY, Sah R, Kerfant BG, Sun H, Gramolini AO, et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci U S A 2006;103:6043–8.
18. Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol 2010;316:165–71.
19. Park HK, Ahima RS. Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism. Metabolism 2015;64:24–34.
20. Hollenberg AN. The role of the thyrotropin-releasing hormone (TRH) neuron as a metabolic sensor. Thyroid 2008;18:131–9.
21. Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong ML, Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metabol 2012;56:597–607.
22. Feldt-Rasmussen U. Thyroid and leptin. Thyroid 2007;17:413–9.
23. Ghamari-Langroudi M, Srisai D, Cone RD. Multinodal regulation of the arcuate/paraventricular nucleus circuit by leptin. Proc Natl Acad Sci U S A 2011;108:355–60.
24. Fierabracci P, Pinchera A, Martinelli S, Scartabelli G, Salvetti G, Giannetti M, et al. Prevalence of endocrine diseases in morbidly obese patients scheduled for bariatric surgery: beyond diabetes. Obes Surg 2011;21:54–60.
25. Kitahara CM, Platz EA, Ladenson PW, Mondul AM, Menke A, Berrington de Gonzalez A. Body fatness and markers of thyroid function among U.S. men and women. PLoS One 2012;7e34979.

Article information Continued

Figure. 1.

Correlations between total body fat changes and thyroid-stimulating hormone (TSH) changes after adjustment.

Table 1.

Anthropometric and metabolic parameters of study subjects (n=49) at baseline versus 3 months after intervention

Variable Baseline* 3 Months P-value
No. of females 11 (22.4) - -
Age (y) 43.9±6.2 - -
Height (cm) 169.9±7.6 - -
Weight (kg) 84.1±12.0 82.7±12.0 <0.001
Body mass index (kg/m2) 29.0±3.5 28.6±3.5 <0.001
Waist circumference (cm) 98.3±8.0 96.9±7.6 <0.001
Hip circumference (cm) 106.6±7.7 105.3±7.1 <0.001
Total fat mass (kg) 28.4±7.1 27.5±6.5 <0.001
Fat free mass (kg) 52.6±8.0 52.2±7.9 0.026
Daily calorie intake (kcal) 2,035.8±503.3 1,771.6±359.8 <0.001
Systolic BP (mm Hg) 132.2±12.0 129.3±9.7 0.056
Diastolic BP (mm Hg) 83.9±8.7 80.9±9.5 0.015
Heart rate (frequency/min) 76.2±8.9 74.7±7.8 0.278
Fasting glucose (mg/dL) 108.3±15.2 106.4±15.0 0.150
Insulin (μIU/mL) 12.3±5.1 11.6±6.3 0.413
Total cholesterol (mg/dL) 212.3±31.5 209.2±29.9 0.446
Triglyceride (mg/dL) 225.7±92.5 203.9±84.2 0.100
High-density lipoprotein cholesterol (mg/dL) 44.6±10.6 43.6±10.2 0.335
Low-density lipoprotein cholesterol (mg/dL) 138.1±32.6 140.8±27.6 0.588
Cortisol (μg/dL) 11.9±4.1 12.0±3.8 0.930
High-sensitivity C-reactive protein (mg/dL) 0.16±0.16 0.12±0.13 0.038
Thyroid-stimulating hormone (μIU/mL) 2.51±1.44 2.54±1.41 0.837
Thyroxin (ng/dL) 1.32±0.12 1.35±0.15 0.222
Current smoking 10 (20.4) - -
Alcohol drinking, yes 34 (69.4) - -
Exercise, yes 25 (51.0) - -
Hypertension 13 (26.5) - -

Values are presented as number (%) or mean±standard deviation by paired t-test.

BP, blood pressure.


Baseline values.

Values after 3 months of weight reduction intervention.

Moderate-intensity exercise.

Table 2.

Partial correlations of thyroid-stimulating hormone changes with other body composition changes

Changes in variable r P-value
Δ Weight (kg) 0.216 0.164
Δ Body mass index (kg/m2) 0.244 0.115
Δ Waist circumference (cm) 0.218 0.160
Δ Total fat mass (kg) 0.395 0.009
Δ Hip circumference (cm) 0.185 0.235
Δ Fat free mass (kg) -0.111 0.477

Δ: mean change in the variable. P-values are presented for partial correlations after the adjustment for age, sex, smoking, alcohol consumption, and moderate-intensity exercise. Statistically significant results are marked in bold.

Table 3.

Metabolic parameters by body fat reduction group

Variable Body fat reduction
>1 kg (n=20) <1 kg (n=29)
Ranges of fat reduction -5.5 to -1.0 -0.9 to 1.9 -
Δ Heart rate (frequency/min) -4.1±11.3 -0.8±6.0 0.388
Δ Glucose (mg/dL) -2.5±7.2 -3.1±9.4 0.860
Δ Insulin (μIU/mL) -2.0±4.4 -2.0±2.9 0.988
Δ Total cholesterol (mg/dL) -8.6±21.1 -1.5±40.8 0.577
Δ Triglyceride (mg/dL) -25.0±64.1 -32.5±60.5 0.768
Δ High-density lipoprotein cholesterol (mg/dL) 0.1±6.8 0.5±8.1 0.918
Δ Low-density lipoprotein cholesterol (mg/dL) -8.4±30.0 10.9±40.5 0.183
Δ Cortisol (μg/dL) 0.1±0.1 -2.1±3.0 0.113
Δ High-sensitivity C-reactive protein (mg/dL) -0.07±0.10 0.03±0.17 0.408
Δ Thyroid-stimulating hormone (μIU/mL) -0.40±0.97 0.33±0.99 0.014
Δ Thyroxin (ng/dL) -0.01±0.17 0.07±0.17 0.238

Values are presented as range or mean±standard deviation. Statistically significant results are marked in bold.


Determined using independent t-test.

Table 4.

Changes in TSH according to body fat reduction

Variable Body fat reduction
P-value* P-value
>1 kg (n=20) <1 kg (n=29)
Δ TSH (μIU/mL) -0.40 (0.97) 0.33 (0.99) 0.014 0.012

Δ: Mean change in the variable. Statistically significant results are marked in bold.

TSH, thyroid-stimulating hormone.


Calculated using the general linear model without adjustment.

Calculated using the general linear model after the adjustment for age, sex, smoking, alcohol consumption, and exercise.